Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Scarlet Therapeutics Raises £3.2m in Funding led by Eos Advisory to advance its RBC platform targeting metabolic diseases.
PRIVATEMay 11, 2026•3 months ago
Amount Raised
£3.2 Million
Round Type
Seed
Bristol
Investors
Daft CapitalOshen BioScvcEos Advisory
Description
Scarlet Therapeutics, a Bristol, UK-based biotechnology company developing red blood cell (RBC) therapies, raised £3.2M in funding. The round was led by new investor Eos Advisory, with participation from existing investor SCVC, and new investors Oshen Bio and Daft Capital. The company intends to use the funds to advance the first applications of its RBC platform, focusing on multiple metabolic diseases. Proceeds will support in vivo proof-of-concept studies, manufacturing development, and regulatory engagement.
Company Information
Company
Scarlet Therapeutics
Location
Bristol, England, United Kingdom
About
Scarlet Therapeutics is a biotechnology company based in Bristol, UK, specializing in the development of engineered red blood cell therapies. Founded in 2022, the company was born as a spin-off of the University of Bristol and the British National Health Service NHS Blood and Transplant. Scarlet Therapeutics aims to create donor-independent blood products targeting metabolic diseases and has potential applications in treating cancers and autoimmune diseases. The company is advancing its RBC platform through proof-of-concept studies and regulatory engagement.
Don't miss Scarlet Therapeutics's next move
Get an email the moment Scarlet Therapeutics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contactsAlistair I., CEO hidden
Predictive Intelligence
Strategic
ML-powered predictions for Scarlet Therapeutics's next move
Bristol